Chromatin remodeling by rosuvastatin normalizes TSC2-/meth cell phenotype through the expression of Tuberin

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 2, 2013, Pages 180-188

  Lesma, Elena ^a   Ancona, Silvia ^a   Orpianesi, Emanuela ^a   Grande, Vera ^a   Di Giulio, Anna Maria ^a   Gorio, Alfredo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; INTERLEUKIN 6; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; REPARIXIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ROSUVASTATIN; S6 KINASE; TUBERIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; EPIGENETICS; FLOW CYTOMETRY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; KIDNEY HEMANGIOMYOLIPOMA; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; SMOOTH MUSCLE FIBER;

ACTINS; ADULT; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROBENZENES; GUANOSINE TRIPHOSPHATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEVALONIC ACID; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIMIDINES; RHOA GTP-BINDING PROTEIN; SULFONAMIDES; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84876587202     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.203141     Document Type: Article

References (41)

1. Arbiser JL, Yeung R, Weiss SW, Arbiser ZK, Amin MB, Cohen C, Frank D, Mahajan S, Herron GS, and Yang J, et al. (2001) The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: Use of telomerase to obtain stable populations of cells from benign neoplasms. Am J Pathol 159: 483-491. (Pubitemid 32751079)
2. Bessler H, Salman H, Bergman M, Straussberg R, and Djaldetti M (2005) In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clin Immunol 117:73-77. (Pubitemid 41725472)
3. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, and Bean J, et al. (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140-151.
4. Bulhak A, Roy J, Hedin U, Sjöquist PO, and Pernow J (2007) Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation. Am J Physiol Heart Circ Physiol 292: H3158-H3163. (Pubitemid 47084571)
5. Carelli S, Lesma E, Paratore S, Grande V, Zadra G, Bosari S, Di Giulio AM, and Gorio A (2007) Survivin expression in tuberous sclerosis complex cells. Mol Med 13:166-177. (Pubitemid 46944959)
6. Castro AF, Rebhun JF, Clark GJ, and Quilliam LA (2003) Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin-and farnesylation-dependent manner. J Biol Chem 278:32493-32496. (Pubitemid 37055685)
7. Chan KK, Oza AM, and Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9:10-19. (Pubitemid 36109711)
8. Demierre MF, Higgins PD, Gruber SB, Hawk E, and Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930-942. (Pubitemid 41766782)
9. Finlay GA, Malhowski AJ, Liu Y, Fanburg BL, Kwiatkowski DJ, and Toksoz D (2007) Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Cancer Res 67:9878-9886. (Pubitemid 47621236)
10. Finlay GA, Malhowski AJ, Polizzi K, Malinowska-Kolodziej I, and Kwiatkowski DJ (2009) Renal and liver tumors in Tsc2(1/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol Cancer Ther 8:1799-1807.
11. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, and Thomas G (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11:1457-1466. (Pubitemid 36776533)
12. Goldstein JL and Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430.
13. Goncharova E, Goncharov D, Noonan D, and Krymskaya VP (2004) TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol 167:1171-1182. (Pubitemid 40066631)
14. Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, and Krymskaya VP (2011) mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol 31:2484-2498.
15. Gorio A, Madaschi L, Zadra G, Marfia G, Cavalieri B, Bertini R, and Di Giulio AM (2007) Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. J Pharmacol Exp Ther 322:973-981. (Pubitemid 47295811)
16. Greenwood J and Mason JC (2007) Statins and the vascular endothelial inflammatory response. Trends Immunol 28:88-98. (Pubitemid 46178495)
17. Grundy SM (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24-33.
18. Inoki K, Corradetti MN, and Guan KL (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37:19-24. (Pubitemid 40070934)
19. Istvan ES and Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160-1164. (Pubitemid 32440937)
20. Iwata A, Shirai R, Ishii H, Kushima H, Otani S, Hashinaga K, Umeki K, Kishi K, Tokimatsu I, and Hiramatsu K, et al. (2012) Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells. Clin Exp Immunol 168:234-240.
21. Jain MK and Ridker PM (2005) Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat Rev Drug Discov 4:977-987.
22. Jiang WG, Sampson J, Martin TA, Lee-Jones L, Watkins G, Douglas-Jones A, Mokbel K, and Mansel RE (2005) Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: The role of promoter methylation of TSC genes. Eur J Cancer 41:1628-1636. (Pubitemid 40981846)
23. Jones PA and Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428. (Pubitemid 34587077)
24. Kim YC, Kim KK, and Shevach EM (2010) Simvastatin induces Foxp31 T regulatory cells by modulation of transforming growth factor-b signal transduction. Immunology 130:484-493.
25. Kodach LL, Jacobs RJ, Voorneveld PW, Wildenberg ME, Verspaget HW, van Wezel T, Morreau H, Hommes DW, Peppelenbosch MP, and van den Brink GR, et al. (2011) Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 60:1544-1553.
26. Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG, and Hall A (2000) The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2:281-287.
27. Lee N, Woodrum CL, Nobil AM, Rauktys AE, Messina MP, and Dabora SL (2009) Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol 9:8.
28. Lesma E, Grande V, Carelli S, Brancaccio D, Canevini MP, Alfano RM, Coggi G, Di Giulio AM, and Gorio A (2005) Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: Epidermal growth factor is the required growth factor. Am J Pathol 167:1093-1103. (Pubitemid 41416260)
29. Lesma E, Grande V, Ancona S, Carelli S, Di Giulio AM, and Gorio A (2008) Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/-smooth muscle cell proliferation. Possible treatment options for TSC and LAM. PLoS ONE 3:e3558.
30. Lesma E, Sirchia SM, Ancona S, Carelli S, Bosari S, Ghelma F, Montanari E, Di Giulio AM, and Gorio A (2009) The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells. Am J Pathol 174:2150-2159.
31. Liu L, Li F, Cardelli JA, Martin KA, Blenis J, and Huang S (2006) Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 25:7029-7040. (Pubitemid 44722071)
32. Liu L, Luo Y, Chen L, Shen T, Xu B, Chen W, Zhou H, Han X, and Huang S (2010) Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J Biol Chem 285:38362-38373.
33. Ma Z, Zhang J, Du R, Ji E, and Chu L (2011) Rho kinase inhibition by fasudil has anti-inflammatory effects in hypercholesterolemic rats. Biol Pharm Bull 34: 1684-1689.
34. Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, and Schaefer EJ (2008) Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol 101:315-318. (Pubitemid 351175627)
35. Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, and Kwiatkowski D (2009) Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer 8:38-46.
36. Rosenson RS, Tangney CC, and Casey LC (1999) Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353:983-984. (Pubitemid 29132615)
37. Sirchia SM, Ramoscelli L, Grati FR, Barbera F, Coradini D, Rossella F, Porta G, Lesma E, Ruggeri A, and Radice P, et al. (2005) Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells. Cancer Res 65:2139-2146. (Pubitemid 40490120)
38. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, and Sabatini DM (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296-1302. (Pubitemid 38991819)
39. Takai Y, Sasaki T, and Matozaki T (2001) Small GTP-binding proteins. Physiol Rev 81:153-208. (Pubitemid 32098004)
40. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, and Issa JP (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96: 8681-8686. (Pubitemid 29354851)
41. Young J and Povey S (1998) The genetic basis of tuberous sclerosis. Mol Med Today 4: 313-319. (Pubitemid 28364109)